Back to News
Market Impact: 0.2
Genmab, Incyte Partner On Trial Of Petosemtamab Combination In KRAS G12D-Mutated Colorectal Cancer
Source: Nasdaq
Healthcare & Biotech
Genmab and Incyte entered a clinical trial collaboration to evaluate a novel combination therapy in patients with metastatic colorectal cancer harboring a KRAS G12D mutation. The announcement addresses a population described as having significant unmet medical needs, but provides no trial results or further details on the therapy.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
GMAB0.50
INCY0.50
More News
- Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
- Biotech stocks are surging. How investors can play the new drug innovation boom
- IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
- Pfizer reports phase 2 data for 25-valent pneumococcal vaccine
- J&J prostate cancer drug shows promising tumor responses in early trial
- Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer